Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness

Anesthesiology

Volumn 122, Issue 5, 2015, Pages 1033-1046

  Fiszer, Dorota ^a,b   Shaw, Marie Anne ^a,b   Fisher, Nickla A ^b   Carr, Ian M ^a   Gupta, Pawan K ^b   Watkins, Elizabeth J ^b   Roiz De Sa, Daniel ^c   Kim, Jerry H ^d   Hopkins, Philip M ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c INSTITUTE OF NAVAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RYANODINE RECEPTOR 1; CACNA1S PROTEIN, HUMAN; CALCIUM CHANNEL; DNA; PRIMER DNA; RYANODINE RECEPTOR;

AMPLICON; CACNA1S GENE; CENTRONUCLEAR MYOPATHY; CLINICAL ARTICLE; CONFERENCE PAPER; DNA EXTRACTION; EXERTIONAL HEAT ILLNESS; EXON; GENE; GENE FREQUENCY; GENOTYPE; HEAT INJURY; HUMAN; MALIGNANT HYPERTHERMIA; NEXT GENERATION SEQUENCING; PATHOGENICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RYR1 GENE; GENETICS; PROCEDURES;

CALCIUM CHANNELS; DNA; DNA PRIMERS; EXONS; HEAT STRESS DISORDERS; HUMANS; MALIGNANT HYPERTHERMIA; POLYMERASE CHAIN REACTION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84937637622     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000610     Document Type: Conference Paper

References (51)

1. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J, Presence of two different genetic traits in malignant hyperthermia families: Implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. A nesthesiology 2002 97 1067 74
2. Brady JE, Sun LS, Rosenberg H, Li G, Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg 2009 109 1162 6
3. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F, In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997 41 955 66
4. Feng W, Barrientos GC, Cherednichenko G, Yang T, Padilla IT, Truong K, Allen PD, Lopez JR, Pessah IN, Functional and biochemical properties of ryanodine receptor type 1 channels from heterozygous R163C malignant hyperthermia-susceptible mice. Mol Pharmacol 2011 79 420 31
5. Protasi F, Paolini C, Nakai J, Beam KG, Franzini-Armstrong C, Allen PD, Multiple regions of RyR1 mediate functional and structural interactions with alpha(1S)-dihydropyridine receptors in skeletal muscle. Biophys J 2002 83 3230 44
6. Bendahan D, Kozak-Ribbens G, Confort-Gouny S, Ghattas B, Figarella-Branger D, Aubert M, Cozzone PJ, A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg 2001 93 683 9
7. Carpenter D, Ringrose C, Leo V, Morris A, Robinson RL, Halsall PJ, Hopkins PM, Shaw MA, The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet 2009 10 104
8. Monnier N, Procaccio V, Stieglitz P, Lunardi J, Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997 60 1316 25
9. Stewart SL, Hogan K, Rosenberg H, Fletcher JE, Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001 59 178 84
10. Brandom BW, Bina S, Wong CA, Wallace T, Visoiu M, Isackson PJ, Vladutiu GD, Sambuughin N, Muldoon SM, Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg 2013 116 1078 86
11. Robinson RL, Anetseder MJ, Brancadoro V, van Broekhoven C, Carsana A, Censier K, Fortunato G, Girard T, Heytens L, Hopkins PM, Jurkat-Rott K, Klinger W, Kozak-Ribbens G, Krivosic R, Monnier N, Nivoche Y, Olthoff D, Rueffert H, Sorrentino V, Tegazzin V, Mueller CR, Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet 2003 11 342 8
12. Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT, Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 2004 287 C1094 102
13. 2+ channel and the type 1 ryanodine receptor. Proc Natl Acad Sci USA 2012 109 7923 8
14. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P, Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006 27 977 89
15. Kim JH, Jarvik GP, Browning BL, Rajagopalan R, Gordon AS, Rieder MJ, Robertson PD, Nickerson DA, Fisher NA, Hopkins PM, Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. A nesthesiology 2013 119 1054 65
16. Carr IM, Morgan JE, Diggle CP, Sheridan E, Markham AF, Logan CV, Inglehearn CF, Taylor GR, Bonthron DT, Illuminator, a desktop program for mutation detection using short-read clonal sequencing. Genomics 2011 98 302 9
17. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR, A method and server for predicting damaging missense mutations. Nat Methods 2010 7 248 9
18. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J, A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014 46 310 5
19. Gillard EF, Otsu K, Fujii J, Duff C, de Leon S, Khanna VK, Britt BA, Worton RG, MacLennan DH, Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 1992 13 1247 54
20. Schiemann AH, Dürholt EM, Pollock N, Stowell KM, Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia. Br J Anaesth 2013 110 122 7
21. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Roméro N, Mezin P, Bendahan D, Payen JF, Depret T, Maclennan DH, Lunardi J, Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005 26 413 25
22. Keating KE, Giblin L, Lynch PJ, Quane KA, Lehane M, Heffron JJ, McCarthy TV, Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: Correlation of the IVCT response with the affected and unaffected haplotypes. J Med Genet 1997 34 291 6
23. Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH, A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991 11 751 5
24. Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V, Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. Hum Mutat 2006 27 830
25. Levano S, Vukcevic M, Singer M, Matter A, Treves S, Urwyler A, Girard T, Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009 30 590 8
26. Tammaro A, Di Martino A, Bracco A, Cozzolino S, Savoia G, Andria B, Cannavo A, Spagnuolo M, Piluso G, Aurino S, Nigro V, Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families. Clin Genet 2011 79 438 47
27. Jeong SK, Kim DC, Cho YG, Sunwoo IN, Kim DS, A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy. J Clin Neurol 2008 4 123 30
28. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA, 1000 Genomes Project Consortium: An integrated map of genetic variation from 1,092 human genomes. Nature 2012 491 56 65
29. Morgan JE, Carr IM, Sheridan E, Chu CE, Hayward B, Camm N, Lindsay HA, Mattocks CJ, Markham AF, Bonthron DT, Taylor GR, Genetic diagnosis of familial breast cancer using clonal sequencing. Hum Mutat 2010 31 484 91
30. Ozcelik H, Shi X, Chang MC, Tram E, Vlasschaert M, Di Nicola N, Kiselova A, Yee D, Goldman A, Dowar M, Sukhu B, Kandel R, Siminovitch K, Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer. J Mol Diagn 2012 14 467 75
31. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE, Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008 10 294 300
32. Urwyler A, Deufel T, McCarthy T, West S, European Malignant Hyperthermia Group Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001 86 283 7
33. Hopkins PM, Ellis FR, Halsall PJ, Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 1991 338 1491 2
34. Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, Booms P, Iles DE, Halsall PJ, Steele DS, Shaw MA, Hopkins PM, Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009 103 538 48
35. Grievink H, Stowell KM, Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia. Orphanet J Rare Dis 2010 5 10
36. Adeokun AM, West SP, Ellis FR, Halsall PJ, Hopkins PM, Foroughmand AM, Iles DE, Robinson RL, Stewart AD, Curran JL, The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree. Am J Hum Genet 1997 60 833 41
37. Heytens L, Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families. Acta Anaesthesiol Belg 2007 58 113 8
38. Fortunato G, Carsana A, Tinto N, Brancadoro V, Canfora G, Salvatore F, A case of discordance between genotype and phenotype in a malignant hyperthermia family. Eur J Hum Genet 1999 7 415 20
39. Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, Iles DE, West SP, Shaw MA, Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet 2000 64 Pt 4 307 20
40. Robinson R, Hopkins P, Carsana A, Gilly H, Halsall J, Heytens L, Islander G, Jurkat-Rott K, Müller C, Shaw MA, Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet 2003 112 217 8
41. Gonsalves SG, Ng D, Johnston JJ, Teer JK, Stenson PD, Cooper DN, Mullikin JC, Biesecker LG, NISC Comparative Sequencing Program Using exome data to identify malignant hyperthermia susceptibility mutations. A nesthesiology 2013 119 1043 53
42. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, McGee S, Do R, Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, Altshuler D, Nickerson DA, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, Akey JM, Broad GO; Seattle GO; NHLBI Exome Sequencing Project Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012 337 64 9
43. Casals F, Bertranpetit J, Genetics. Human genetic variation, shared and private. Science 2012 337 39 40
44. Klein A, Lillis S, Munteanu I, Scoto M, Zhou H, Quinlivan R, Straub V, Manzur AY, Roper H, Jeannet PY, Rakowicz W, Jones DH, Jensen UB, Wraige E, Trump N, Schara U, Lochmuller H, Sarkozy A, Kingston H, Norwood F, Damian M, Kirschner J, Longman C, Roberts M, Auer-Grumbach M, Hughes I, Bushby K, Sewry C, Robb S, Abbs S, Jungbluth H, Muntoni F, Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum Mutat 2012 33 981 8
45. Duarte ST, Oliveira J, Santos R, Pereira P, Barroso C, Conceição I, Evangelista T, Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms. Muscle Nerve 2011 44 102 8
46. Carpenter D, Ismail A, Robinson RL, Ringrose C, Booms P, Iles DE, Halsall PJ, Steele D, Shaw MA, Hopkins PM, A RYR1 mutation associated with recessive congenital myopathy and dominant malignant hyperthermia in Asian families. Muscle Nerve 2009 40 633 9
47. Department of the Surgeon General. Climatic Illness and Injury in the Armed Forces: Force Protection and Initial Medical Treatment 2014 London Ministry of Defence. JSP 539. V2.4
48. Gardner JW, Kark JA, Pandolf KB, Burr RE, Clinical diagnosis, management, and surveillance of exertional heat illnesses, Medical Aspects of Harsh Environments, volume 1 2002 Washington D.C. The Office of the Surgeon General at TMM Publications 231 80
49. Bouchama A, Knochel J, Heat stroke. New Engl J Med 2004 346 1987 8
50. Defence Medical Services Department Op TELIC: Heat Related Illness Audit 2003 London Ministry of Defence. DMSD/962/30/1, 1-11.
51. Ramanathan N, A new weighting system for mean surface temperature of the human body. J Appl Physiol 1964 19 531 3